The Medicines and Healthcare products Regulatory Agency has approved semaglutide, marketed as Wegovy, for the treatment of metabolic-associated steatohepatitis, or MASH, in adults with moderate-to-advanced liver fibrosis. According to the MHRA announcement issued on 3 July 2026, the decision adds a new indication to a medicine already authorised for weight management and for reducing cardiovascular events in adults. The approval extends the role of a widely used GLP-1 medicine into a liver disease setting. It also places the focus on the terms of authorisation, because the regulator has approved the treatment with conditions attached rather than granting an unrestricted, full marketing authorisation at this stage.
MASH is the inflammatory form of fatty liver disease and develops when excess fat in the liver leads to inflammation and scarring. The MHRA says the condition is more likely in people with obesity, type 2 diabetes or raised blood lipid levels, which places the treatment decision within a broader metabolic disease context rather than a purely hepatology pathway. That matters for service planning as well as prescribing. The patient group most likely to be considered for treatment will often have overlapping clinical risks, meaning any rollout will sit across obesity care, diabetes management and specialist liver services.
The legal basis for the decision is a conditional marketing authorisation. In practical terms, that means the MHRA considers the available evidence sufficient to permit use in the approved patient group, while requiring additional confirmatory evidence before a full marketing authorisation can be issued. The agency states that further results from an ongoing study in adults with MASH and moderate-to-advanced liver scarring must still be submitted. It has also said that new information on the medicine will be reviewed at least once a year, with the Summary of Product Characteristics updated where necessary.
For patients, the immediate access position is narrower than the approval headline may suggest. The MHRA states that semaglutide is not currently available on the NHS for MASH, because routine NHS use depends on a separate decision from the National Institute for Health and Care Excellence, which is appraising its clinical and cost effectiveness for this indication. This distinction is standard in the health policy process. A regulator decides whether a medicine meets the required threshold for quality, safety and efficacy, while NICE separately considers whether it represents value for money and should be adopted in routine NHS care.
The MHRA says semaglutide remains a prescription-only medicine and should be used alongside diet and exercise. Treatment starts at 0.25 mg once weekly and is then increased in stages to 0.5 mg, 1 mg and 1.7 mg, with four weeks on each dose, before reaching a maintenance dose of 2.4 mg once weekly. For patients with obesity, defined in the announcement as a body mass index above 30, the dose can be increased to 7.2 mg once weekly after at least four weeks on 2.4 mg. The product acts as a GLP-1 receptor agonist, mimicking a hormone released after eating and helping patients feel fuller for longer while reducing food cravings.
Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the available evidence shows semaglutide to be a safe and effective option for patients with MASH, while stressing that it should only be taken in consultation with a doctor. That is consistent with the regulatory approach to GLP-1 medicines, where prescribing decisions require clinical supervision and dose escalation needs to be managed carefully. The common adverse effects identified by the MHRA are gastrointestinal, including nausea, diarrhoea, constipation and vomiting. The agency says anyone who suspects a side effect should speak to a doctor, pharmacist or nurse and may also report it through the Yellow Card scheme.
The new indication was authorised for Novo Nordisk on 3 July 2026. The MHRA says the updated Summary of Product Characteristics and Patient Information Leaflet will be published on its products website within seven days of approval. The next steps are therefore clear. Clinicians will need the final prescribing information, patients will be watching the NICE appraisal, and the long-term status of the indication will depend on whether the ongoing study confirms the medicine's efficacy and safety profile in MASH.